D’Arcy v Myriad Genetics Inc

High Court of Australia · 2015

Intellectual Property And Technology LawPatents

D’Arcy v Myriad Genetics Inc (2015) 258 CLR 334

Isolating the BRCA1 sequence took enormous work, and the isolated product does not occur in the cell. Was what was claimed an invention?

What happened?

Myriad held a patent whose claims 1 to 3 were expressed as product claims to isolated nucleic acid coding for all or part of a mutant or polymorphic BRCA1 polypeptide — a sequence associated with breast and ovarian cancer risk. D’Arcy challenged the claims on the ground that they were not a “manner of manufacture” under s 18(1)(a) of the Patents Act 1990 (Cth). She succeeded neither at first instance nor in the Full Court of the Federal Court.

What did the Court decide?

The appeal was allowed: claims 1 to 3 did not meet s 18(1)(a) ([95]).

Proposition

What is the principle?Includes ratio and obiter analysis

Principle analysis

A claim must be characterised by its substance, not its form, before it is tested against “manner of manufacture” in s 18(1)(a) of the Patents Act 1990 (Cth). Claims to isolated nucleic acids coding for a mutated or polymorphic BRCA1 polypeptide were, in substance, claims to “information embodied in arrangements of nucleotides” — information that “is not ‘made’ by human action. It is discerned” ([6]). That the claimed product was in a formal sense created by human action “is not sufficient to support its characterisation as a manner of manufacture”; extending the concept to that class of claim was “not appropriate for judicial determination” ([94]).

D’Arcy invoked the United States Supreme Court’s description of the claims before it — that they were “not expressed in terms of chemical composition”, did not rely “on the chemical changes that result from the isolation of a particular section of DNA”, and instead “focus on the genetic information encoded in the BRCA1 and BRCA2 genes” — and submitted that the chemical, structural and functional differences Myriad relied on played no part in the definition of the invention as claimed here ([90]). The Australian claims in issue concerned BRCA1.

French CJ, Kiefel, Bell and Keane JJ accepted that characterisation to the extent that it emphasised the focus on genetic information ([90]). Their reasons also treated the natural-product and artificial-product categories as potentially distracting from the issue raised by these claims ([91]). The refusal to extend the concept concerned this class of claim; including it would not contribute to coherence in the law ([94]). This does not establish a general prohibition on patenting isolated natural substances.

Ratio and obiter

Ratio is reasoning necessary to the decision; obiter is an observation not necessary to it. Read each passage in context. The links open the judgment in a new tab; use the cited paragraph or report page.

Ratio · French CJ, Kiefel, Bell and Keane JJ

Read judgment: [6] (PDF p 10) (opens in a new tab), [88] (PDF p 47) (opens in a new tab), [93]–[95] (PDF p 49) (opens in a new tab)

These four Justices formed a majority of the seven-member Court. Their characterisation of claims 1–3 by substance was necessary to rejecting the Full Court’s treatment of them as chemical products. The claims concerned genetic information that isolation did not make; their breadth and potential chilling effect also weighed against extending manner of manufacture to this class of claim. Those reasons led directly to the conclusion that claims 1–3 failed s 18(1)(a). The classification concerns this ground of decision, not a general prohibition on patenting isolated natural substances. Gageler and Nettle JJ and Gordon J agreed in the orders through separate reasons.

Why does this case matter?

Because the requirement bit, and bit here. Manner of manufacture is usually argued about computer-implemented inventions, and it is easy to treat it as a niche objection with a settled answer everywhere else. A patent over an isolated human gene sequence, granted, upheld at first instance and upheld again by a Full Court, failed on it.

It is also a case that shows how consequences enter a subject-matter argument. The Court was not indifferent to policy — it weighed the chilling effect on innovation and the breadth of the monopoly a claim of this kind would confer ([8], [93]) — and it did not disclaim incremental judicial development of the concept, which it treated as proper ([5], [23]–[25]). Use those passages to identify the practical consequences each side would need to address in a subject-matter dispute.

Exam and application relevance

Compare the wording of the disputed product claims with a hypothetical claim to the isolation process. Would the same reasoning apply to both? Identify the passages needed to support your answer.

Keep the requirements separate, and state them correctly. Manner of manufacture (s 18(1)(a)) asks what is being claimed. Novelty (s 18(1)(b)(i), s 7(1)) asks whether the invention is anticipated by the prior art base. Inventive step (s 18(1)(b)(ii), s 7(2)–(3)) asks whether it would have been obvious to a person skilled in the relevant art in the light of common general knowledge and specified prior art information. None of the three measures how much effort was expended, and an answer that treats “they worked very hard” as an argument has not engaged with any of them.

For a different isolated substance, identify which features of the BRCA1 claims would need comparison before relying on Myriad.

Check your understanding

Your client’s claim is to a purified compound found in a plant, and the purification took a decade. Which requirement does the decade go to, and which does it not touch?